AI And The New Paradigm Of Drug Discovery
Clinical Research / Clinical Trials, Digital & Tech
Anchored By: Ciara Clancy - CEO, Beats Medical Ltd.
Participants include:
The drug discovery landscape is changing, with artificial intelligence accelerating and reimagining traditional research and development processes. This paradigm shift leverages machine learning, deep learning, and computational modeling to predict molecular behavior, identify novel therapeutic targets, and design compounds with efficiency. Beyond reducing time and costs, AI approaches are enabling researchers to explore previously inaccessible chemical spaces and biological mechanisms.
This discussion will examine how AI technologies are revolutionizing each stage of the drug discovery pipeline, creating opportunities to address complex diseases while raising important considerations about validation methodology, regulatory frameworks, and equitable access to innovation.
Join us to discuss:
How can AI-powered approaches overcome traditional bottlenecks in drug discovery while maintaining scientific rigor and reproducibility?
What validation frameworks and benchmarks should guide the implementation of AI models in pharmaceutical research and development?
How might these technological advances bridge the gap between computational predictions and clinical translation to deliver meaningful therapeutic breakthroughs?
There is nothing here right now, check back at a later date.